Search clinical trials for: EP0057

Total 91 results

Peplin
TKL Research, Inc.

Completed

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Actinic Keratosis

United States, Australia
Peplin

Completed

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

Superficial Basal Cell Carcinoma

United States
Peplin
LEO Pharma

Completed

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

Healthy | Actinic Keratosis

United States
Peplin

Completed

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Dermavant Sciences GmbH

Completed

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Ellipses Pharma

Recruiting

Study to Evaluate the Safety and Tolerability of EP0042

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia, Netherlands, United Kingdom
Peplin

Completed

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Keratosis

United States
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Actinic Keratosis

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Ellipses Pharma

Recruiting

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Advanced Solid Tumor

United States, Spain, United Kingdom
Peplin

Completed

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Actinic Keratosis

United States
Peplin

Withdrawn

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Warts

Australia
Peplin

Completed

Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005

Actinic Keratoses

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

Carcinoma, Squamous Cell

Australia
Peplin

Completed

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Dermavant Sciences GmbH

Completed

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Peplin

Completed

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Seborrheic Keratosis

Australia
Eisai Inc.

Completed

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

United States
Eisai Inc.

Terminated

A Study of E2007 In Patients With Parkinson's Disease

Parkinson's Disease

United States
Eisai Co., Ltd.

Completed

Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects

Healthy Volunteers

Japan
Peplin
Omnicare Clinical Research

Completed

A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

Actinic Keratosis

United States
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
EA Pharma Co., Ltd.

Completed

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Healthy Male Participants

United Kingdom
Dermavant Sciences GmbH

Completed

A Study of E6005 in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Eisai Inc.

Completed

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Migraine Prophylaxis

United States
Peplin

Completed

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

Actinic Keratosis

United States, Australia
Peplin

Completed

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin

Photo-damage

Australia
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Inflammatory Bowel Disease

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Ellipses Pharma

Recruiting

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

Metastatic Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States, Spain, United Kingdom
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Actinic Keratoses

United States
Peplin

Completed

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial Cancer

United States
EA Pharma Co., Ltd.

Completed

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Moderate Active Ulcerative Colitis

Japan
Eisai Co., Ltd.

Completed

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Epilepsy

Germany
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Circassia Limited

Completed

Phase III Cat-PAD Follow-on Study

Cat Allergy
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States, Australia
Eisai Inc.

Completed

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Epilepsy

United States, Latvia
Eisai Korea Inc.

Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Korea, Republic of

3

Subscribe